Background: The duration of protection after hepatitis B ... antibody titers, 61% (33 of 54) and 67% (8 of 12), respectively, responded to a booster dose. In children of HBsAg-positive mothers ...

Discover a recent study presented at EASL 2025 that explored the impact of opt-out testing for blood-borne viruses in ...

Vir Biotechnology, Inc. progresses HDV treatment with promising ECLIPSE program results. Click here to find out why VIR stock ...

Spontaneous loss of hepatitis B e antigen (HBeAg ... optimal drug regimen and timing of therapy for a patient with HBeAg-positive hepatitis. Accreditation: Tufts University School of Medicine ...

Discover an awarding winning abstract from EASL 2025 that has called for more person-centred hepatitis screening. Learn more.

Updated Hep B Vaccine More Effective for People With HIV Dec. 10, 2024 — A newer vaccine against hepatitis B virus was clearly superior to an older vaccine type in inducing a protective antibody ...

antinuclear antibody titre ≥1:320, evidence of hepatitis B, hepatitis C or HIV infection, known sensitivity to methotrexate (MTX), sulphasalazine or hydroxychloroquine and systemic disease likely to ...

Vir Biotechnology’s sidelined hepatitis B candidate, designed to serve as a “functional cure,” has failed to achieve the ...

Vir Bio (VIR) reveals 24-week post-end-of-treatment data from a mid-stage trial for its Hep B therapy developed with Xencor ...

Strong synergistic effect on fat mass (77% reduction) was observed when the Activin E antibody was combined with a GLP-1 receptor agonist, resulting in total weight loss of 35.3%, 7.5% greater ...

Introduction: Infection with hepatitis B virus (HBV) and human immunodeficiency virus (HIV) is a public health problem ...

An antisense drug in development at GSK has shown further activity against hepatitis B virus (HBV) in a mid-stage trial, setting up a phase 3 assessment next year to see if it could offer a ...